Description du projet
Améliorer la santé cardiovasculaire des personnes âgées grâce à la polypill
Le traitement des maladies cardiovasculaires (MCV) implique souvent une combinaison de médicaments, à laquelle les patients n’adhèrent souvent pas d’une manière optimale. Cette faible adhésion réduit l’efficacité et le bénéfice clinique, aggrave les symptômes de la maladie et augmente la mortalité. Le projet SECURE, financé par l’UE, souhaite évaluer une polypill à dose fixe pour la prévention cardiovasculaire secondaire chez les personnes âgées de 65 ans et plus. Il évaluera, dans le cadre d’un essai clinique, les avantages potentiels de la polypill en tant que stratégie de traitement bon marché et accessible dans le monde entier, en la comparant au traitement standard. Ses objectifs secondaires consisteront notamment à évaluer l’adhésion, le contrôle des facteurs de risque, l’impact pharmaco-économique, les différences régionales et à élaborer des lignes directrices et des recommandations cliniques.
Objectif
While Cardiovascular diseases (CVD) are the main cause of death worldwide, they are responsible for half of all deaths in Europe. The overall ageing of the European population and improving survival of patients with coronary heart disease has created a large population of older adults eligible for secondary prevention. Despite the established efficacy of cardiovascular medications, suboptimal adherence reduces their effectiveness and is the primary reason for suboptimal clinical benefit, contributing significantly to worsening of diseases and deaths at the population level. SECURE will be the first trial testing the efficacy of a fixed dose combination (FDC) polypill for secondary cardiovascular prevention in the elderly population (≥ 65 years old). The main objective is to evaluate the potential benefit of the FDC as a component of a cost-effective, globally available and comprehensive treatment strategy for secondary prevention of cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, stroke, and hospitalisation requiring revascularisation) as compared to standard therapy (the three components of the polypill given separately). As part of the secondary endpoints, SECURE will compare the effect of both strategies on adherence and intermediate measures of risk factor control such as lipids and blood pressure. Importantly, it will also measure the pharmacoeconomic impact of the FDC intervention as well as regional differences in all outcomes. The five-year project will thus involve subjects from seven different countries: Spain, Italy, France, Germany, Hungary, Poland and the Czech Republic. The findings and conclusions obtained in SECURE will allow the drafting of clinical guidelines and recommendations that will provide useful guidance and will serve as a reference framework for all stakeholders involved in tackling major challenges related to secondary prevention and treatment of chronic diseases in the elderly population.
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- natural sciencesbiological sciencesbiochemistrybiomoleculeslipids
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- medical and health sciencesbasic medicineneurologystroke
- social sciencespolitical sciencesgovernment systems
Mots‑clés
Programme(s)
Thème(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
28029 Madrid
Espagne